Suppr超能文献

Toll 样受体在人乳腺癌中的表达谱。

Expression profile of Toll‑like receptors in human breast cancer.

机构信息

Shandong Provincial Key Laboratory of Animal Resistance Biology, College of Life Sciences, Shandong Normal University, Jinan, Shandong 250014, P.R. China.

出版信息

Mol Med Rep. 2020 Feb;21(2):786-794. doi: 10.3892/mmr.2019.10853. Epub 2019 Nov 26.

Abstract

Toll‑like receptors (TLRs) are the most widely studied pattern recognition receptors. Mounting evidence suggests an important association between TLRs and the occurrence and development of breast cancer. Thus, targeting these receptors may be a potential strategy for breast cancer treatment. The current study analyzed the data of 1,215 patients with breast cancer obtained from The Cancer Genome Atlas (TCGA) database. It was observed that, in addition to TLR6, TLR7 and TLR8, the expression of the remaining TLRs in breast cancer tissues was lower than that in normal tissues. In addition, TLR3 and TLR9 displayed significantly different expression levels in ER‑/PR‑negative breast cancer compared with the control tissues, while TLR5 expression was significantly reduced in HER2‑enriched breast cancer. Furthermore, TLR10 exhibited lower expression levels in advanced stages of the disease as compared with that observed in earlier stages. Survival analysis revealed that the expression of TLR4 and TLR7 had a significant impact on survival, and higher expression levels suggested worse prognosis. Finally, the expression levels of TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10 were correlated with those of the inflammatory cytokines interleukin‑1β and tumor necrosis factor‑α, while the expression levels of TLR3, TLR7, TLR8 and TLR9 were correlated with those of interferon‑β and C‑X‑C motif chemokine ligand 10. Taken together, the current study results suggest that TLR expression may serve as a biomarker of cancer pathogenesis and progression, and may provide new insights for the treatment of breast cancer through the regulation and targeting of TLRs.

摘要

Toll 样受体(TLRs)是研究最为广泛的模式识别受体。越来越多的证据表明,TLRs 与乳腺癌的发生和发展之间存在重要关联。因此,靶向这些受体可能是治疗乳腺癌的一种潜在策略。本研究分析了来自癌症基因组图谱(TCGA)数据库的 1215 例乳腺癌患者的数据。结果观察到,除 TLR6 外,TLR7 和 TLR8 在乳腺癌组织中的表达也低于正常组织。此外,TLR3 和 TLR9 在 ER-/PR-阴性乳腺癌中的表达与对照组织相比存在显著差异,而 TLR5 在 HER2 富集型乳腺癌中的表达显著降低。此外,TLR10 在疾病晚期的表达水平较早期阶段更低。生存分析显示,TLR4 和 TLR7 的表达对生存有显著影响,高表达水平提示预后较差。最后,TLR1、TLR2、TLR4、TLR5、TLR6 和 TLR10 的表达水平与炎症细胞因子白细胞介素-1β和肿瘤坏死因子-α的表达水平相关,而 TLR3、TLR7、TLR8 和 TLR9 的表达水平与干扰素-β和 C-X-C 基序趋化因子配体 10 的表达水平相关。综上所述,本研究结果表明,TLR 的表达可能作为癌症发病机制和进展的生物标志物,并可能通过 TLR 的调节和靶向治疗为乳腺癌的治疗提供新的思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b73e/6947885/c58257f2ba9e/MMR-21-02-0786-g00.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验